Pharmacoeconomic/health economic, quality-of-life and outcomes research study results for the following diseases will be presented.

PDF File is available. See Poster/Podium Presentations-PDF Files index.

METHODOLOGY ISSUES II
Moderator: Kent Summers RPh, PhD, Research Scientist, Eli Lilly & Company, Indianapolis, IN, USA
MI5	EXPLORING THE DERIVATION OF UTILITY VALUES USING A DISCRETE-CHOICE CONJOINT ANALYSIS METHOD – A COST-UTILITY ANALYSIS OF GEMCITABINE PLUS CISPLATIN FOR THE TREATMENT OF BLADDER CANCER Davey P1, Rajan N2, 1M-TAG, Sydney, NSW, Australia; 2Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia
MI6	ARE THE FRAMINGHAM-RISK EQUATIONS VALID FOR EUROPE? Wendland G1, Lauterbach K2, 1Cologne, NW, Germany; 2University of Cologne, Cologne, Germany
MI7	HOSPITAL-SPECIFIC RELATIVE INTENSITY SCORES FOR PHARMACEUTICAL SERVICES Foster DA, Solucient, LLC, Ann Arbor, MI, USA
MI8	DEVELOPING A QUALITY APPRAISAL INSTRUMENT TO EVALUATE THE PEDIATRIC HEALTH ECONOMICS LITERATURE Ungar WJ1, Menon D2, Lee A1, Stafinski T2, 1The Hospital for Sick Children Research Institute, Toronto, ON, Canada; 2Institute of Health Economics, Edmonton, AB, Canada
HEALTH POLICY – CONSUMER ADVERTISING ISSUES
Moderator: David Veenstra PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes Research & Policy Program, University of Washington, Seattle, WA, USA
HP5	THE RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING AND CLINICIAN BEHAVIORAL INTENTIONS Zachry III WM, Jackson TR, The University of Arizona, Tucson, AZ, USA
HP6	RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING SPENDING AND DRUG PRICING FOR THE TOP TWENTY DRUGS FROM 1997 TO 2000: AN EXPLORATORY STUDY Parthan AG, Anantharaman RT, Shepherd MD, The University of Texas at Austin, Austin, TX, USA
HP7	IMPACT OF DIRECT TO CONSUMER ADVERTISING - THE CONSUMER SEARCH FOR INFORMATION Belazi DT1, Crawford A2, Pizzi L2, 1Thomas Jefferson University & Abbott Laboratories, Philadelphia, PA, USA; 2Thomas Jefferson University, Philadelphia, PA, USA
HP8	FDA REGULATORY ACTIONS AGAINST MISLEADING OR UNSUBSTANTIATED ECONOMIC AND QUALITY-OF-LIFE CLAIMS: AN ANALYSIS OF WARNING LETTERS AND NOTICES OF VIOLATION Stewart KA, Neumann PJ, Harvard School of Public Health, Boston, MA, USA
ASTHMA & RESPIRATORY DISORDERS/INFECTIONS
Moderator: George Torrance PhD, Professor Emeritus, McMaster University and Vice President, Innovus Research, Inc., Burlington, Ontario, Canada
AR1	RELATIONSHIP BETWEEN DIFFERENT MEASURES OF ASTHMA SEVERITY: PATIENT-PERCEIVED, SYMPTOM DERIVED, AND FEV1 DETERMINED SEVERITY MEASURES Erickson SR, Kirking DM, Bria WF, University of Michigan, Ann Arbor, MI, USA
AR2	DIRECTLY ELICITED PREFERENCES COMPARED TO PREFERENCES DERIVED FROM THE SF-36 IN ADULT ASTHMATICS Lee TA1, Hollingworth W2, Sullivan SD3, 1Hines VA Hospital, Hines, IL, USA; 2University of Cambridge, Cambridge, UK; 3University of Washington, Seattle, WA, USA
AR3	MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA Drummond M1, Becker D2, Hux M2, Chancellor J3, Duprat-Lomon I4, Sagnier PP5, 1Innovus Research (UK) Ltd. and University of York, Heslington, York, UK; 2Innovus Research Inc, Burlington, ON, Canada; 3Innovus Research (UK) Ltd, Amersham, Buckinghamshire, UK; 4Bayer Pharma, Puteaux, France; 5Bayer plc, Slough, UK
AR4	PSYCHOMETRIC PROPERTIES OF THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE IN AN INTERNATIONAL SAMPLE Margolis MK1, Frank L1, Leidy NK1, Duprat-Lomon I2, Amiot N2, Sagnier PP3, 1MEDTAP International, Bethesda, MD, USA; 2Bayer Pharma, Puteaux, France; 3Bayer plc, Slough, UK
NEUROLOGICAL/PAIN DISORDERS
Moderator: David Matchar MD, Director and Professor of Medicine, Duke Center for Clinical Health Policy Research, Durham, NC, USA
NP1	INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES Mychaskiw MA, Thomas III J, Purdue University, West Lafayette, IN, USA
NP2	EXCESSIVE COSTS RESULTING FROM PRIMARY CARE AND CHIROPRACTIC UTILIZATION OF DIAGNOSTIC IMAGING IN THE FIRST WEEK OF CARE FOR ACUTE LOW BACK PAIN Jackson SL1, Kim S2, Seifelden R2, Papatheofanis F3, 1Aequitas Consulting Group, San Diego, CA, USA; 2Purdue Pharma, Stamford, CT, USA; 3University of California San Diego, La Jolla, CA, USA
NP3	AN ITEM ANALYSIS OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) USING CLASSICAL TEST THEORY AND ITEM RESPONSE THEORY METHODS Ayyar Krishnan A1, Kwong WJ2, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA
NP4	TOTAL HEALTHCARE EXPENDITURES FOR MIGRAINE PATIENTS ASSOCIATED WITH CHOICE OF DRUG THERAPY Schabert VF1, Esposito D1, Bowers BW2, Rousey A1, Tillotson F1, 1The MEDSTAT Group, Santa Barbara, CA, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA

The Rise of Consumerism
 
The evolution of managed care has given rise to the consumer as the most powerful entity in the setting of coverage priorities. With increased emphasis on direct-to-consumer (DTC) promotion and the Internet’s disintermediation, consumers have become more knowledgeable and more opinionated about the treatments they want covered. This session will discuss how managed care is changing to accommodate the consumer’s interests, what consumers want from managed care, how to provide consumers with information that can help them make wise decisions, and methods to evaluate the impact of consumer preferences and decision-making on the outcomes of care. Implications for outcomes researchers will be discussed.

Moderator: Eva Lydick PhD, ISPOR 2001-2002 President and Director of Epidemiology, AstraZeneca, Wilmington, DE, USA

"Consumers Taking Control of Their Own Healthcare"

Speaker: Linda F. Golodner, Executive Director, National Consumer League, Washington, DC, USA

"Empowered or Overwhelmed? Making the Health System Work for Consumers"

Speaker: Karen Donelan ScD, Senior Vice President, Medrock, Cambridge, MA, USA

"The Consumer Perspective"

Discussant: Charles Inlander, President, People's Medical Society, Fogelsville, PA, USA.

"Implications for Outcomes Researchers"

Discussant: Newell McElwee PharmD, MSPH, Senior Director/Team Leader, Global Outcomes Research, Pfizer, Inc, New York, NY, USA

Presentations: ISPOR Contributed Podium and Poster Presentation Awards
 

  Click here to view podium presentations